Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.

ABSTRACT:

SUBMITTER: Giordano C 

PROVIDER: S-EPMC12078852 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature